Everyone who signs our petition to the World Health Organization (WHO) has a why they would like to see #ovariancancer recognised as a global priority. What is yours? Sign now in honour of #WOCD2024 so we can get to #NoWomanLeftBehind .

✍️bit.ly/GlobalPriority

#WorldOvarianCancerDay

Radiation Therapy With or Without Cisplatin for Local Recurrences of Endometrial Cancer: Results From an NRG Oncology/GOG Prospective Randomized Multicenter Clinical Trial | Journal of Clinical Oncology ascopubs.org/doi/abs/10.120… #gyncsm

Hypofractionated IMRT with concurrent chemotherapy appears to be well tolerated as post-operative treatment in patients with #cervicalcancer . Published in JAMA Oncology. brnw.ch/21wJnEj #gyncsm

🔸️NCT06394804
🎯
🔹️A Study of Avutometinib, Defactinib, and Letrozole in People With Low-Grade Serous Ovarian Cancer (CHAMELEON).
🔹️Outside of clinical trials, there's very little to offer to women with #LGSOC type of #ovariancancer in both, frontline and recurrent setting.

Apply now for the #ESMOPreceptorship on #UterineCancer : multidisciplinary management, standards of care, therapeutic targets and future perspectives.
🌏 Lugano (CH), 11-12 July 2024.
📍 Deadline to apply: 06 May 2024.
ow.ly/9PnH50Ruofw
Ilaria Colombo Ray-Coquard Isabelle #GynCSM

Ramez N. Eskander, MD, discusses updated data for pembrolizumab plus chemotherapy in patients with advanced/recurrent endometrial cancer. Ramez Eskander @UCSD_OBGYN @sgo_org @SGOMtg #gyncsm onclive.com/view/pembroliz…

We are delighted to announce the launch of The IGCS-IJGC Evidence Based Medicine for Gynecologic Oncology (EBM on the Go) Certificate Program! EBM integrates clinical expertise with the best available evidence and patients’ values & preference.

igcs.org/ebm-on-the-go/

#OvarianCancer is on the rise, and if we do not change the status quo, by 2050 8 million lives will be lost to this disease. The #TimeToAct is now. Sign our petition to the World Health Organization (WHO) so we can get to #NoWomanLeftBehind .

Sign here: bit.ly/GlobalPriority. #WOCD2024

As we get ready to observe #WorldOvarianCancerDay on May 8, it’s important to mention that May is also #HysterectomyAwarenessMonth .

Almost all patients diagnosed with ovarian cancer, and many patients diagnosed with other gyn cancers, need surgery. 1/2

Thank you Amanda Nickles Fader, MD and SGO for your important leadership in the fight against gynecologic cancer.

NOCC's Financial Assistance Program understands the challenges of clinical trial participation. Our clinical trial fund helps cover the non-medical costs associated with clinical trial participation. To learn more and apply, visit our website today. bit.ly/3JHWGWr

WATCH NOW! 👉Immunotherapy and its impact on overall survival in patients with recurrent endometrial cancer

igcs.org/educational-we…

The SGO is now seeking Early Career Member applicants to serve as Committee Observers for the 2024 program year. This is an opportunity for members to learn about SGO/FWC leadership opportunities and organizational structure.

Apply here:
allsgofwc.typeform.com/to/OE5c8vUQ

#gyncsm community - Note that we will not hold a chat in May 2024.

Miss our latest chat? You can read the Immunotherapies recap on our blog: gyncsm.blogspot.com/2024/03/march-…

Save the Date for our remaining 2024 chats:
Jun 12, Sep 11, and Dec 11.

The results of NRG Oncology The GOG Foundation Inc. #238: addition of #cisplatin to #radiationtherapy does not appear to improve progression-free survival for patients with localized recurrent #endometrialcancer . Now online in Journal of Clinical Oncology. From Physician's Weekly.

#gyncsm

physiciansweekly.com/the-addition-o…

Established in 2013 by a group of leaders from ovarian cancer advocacy organizations around the world, May 8 – World Ovarian Cancer Day, is the one day of the year we globally raise our voices in solidarity in the fight against ovarian cancer.

Change your profile pic for #WOCD2024 ! We've created a #WorldOvarianCancerDay frame for social media channels' profile pictures. With the easy to use Canva template, you can help us get closer to #NoWomanLeftBehind & #NoPersonLeftBehind

Create yours here: loom.ly/4LkC3xU

.U.S. FDA Approves Tisotumab Vedotin-tftv for Recurrent or Metastatic Cervical Cancer ascopost.com/news/april-202… #gyncsm #cervicalcancer FDA Oncology #oncology

Data from the phase 3 NRG-GY018/KEYNOTE-868 trial could establish pembrolizumab plus chemotherapy as a new standard of care for patients with advanced or recurrent endometrial cancer, if approved by the FDA. Ramez Eskander @UCSD_OBGYN @sgo_org #SGOMtg #gyncsm onclive.com/view/pembroliz…

Adding cisplatin to radiation doesn't improve progression-free survival for localized recurrent #endometrialcancer but does increase treatment-related toxicity. Radiation remains standard of care. ascopubs.org/doi/10.1200/JC… Journal of Clinical Oncology Ann Klopp David Scott Miller #gyncsm #gynonc